Liposomal mitoxantrone with immunotherapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have nasopharyngeal carcinoma that has returned or spread and hasn't responded to platinum-based chemotherapy.
- You must have previously received a PD-1 or PD-L1 inhibitor and your cancer progressed during or shortly after treatment.
- You must be between 18 and 70 years old.
- You must be in good physical condition (able to carry out daily activities without help).
- You must have at least one tumor that can be measured on a CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
This trial tests a combination of two drugs, irinotecan liposome and S-1, for people with a type of nose and throat cancer that has spread or come back after treatment with immunotherapy (PD-1/L1 inhibitors). The goal is to see if this new combination can help when standard treatments have stopped working.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests whether adding a new drug (BL-B01D1) to an immunotherapy maintenance treatment can help keep nasopharyngeal cancer from growing after initial chemotherapy. It aims to improve how long patients live without the cancer progressing.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.